Immediate evaluation of global longitudinal strain at initiation of trastuzumab treatment in breast cancer patients
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Immediate evaluation of global longitudinal strain at initiation of trastuzumab treatment in breast cancer patients. / Banke, Ann; Schou, Morten; Ewertz, Marianne; Dahl, Jordi; Frederiksen, Peter Hartmund; Videbæk, Lars; Cold, Søren; Møller, Jacob E.
I: Echocardiography, Bind 38, Nr. 10, 2021, s. 1702-1710.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Immediate evaluation of global longitudinal strain at initiation of trastuzumab treatment in breast cancer patients
AU - Banke, Ann
AU - Schou, Morten
AU - Ewertz, Marianne
AU - Dahl, Jordi
AU - Frederiksen, Peter Hartmund
AU - Videbæk, Lars
AU - Cold, Søren
AU - Møller, Jacob E.
N1 - Publisher Copyright: © 2021 Wiley Periodicals LLC
PY - 2021
Y1 - 2021
N2 - Background: Global longitudinal strain (GLS) is recommended to detect subclinical changes preceding reduced left ventricular ejection fraction (LVEF) in trastuzumab related cardiotoxicity. Since the possibility to detect signs of acute myocardial deterioration at treatment initiation is not clarified, the objective of this study was to assess changes in GLS and biomarkers within the first 2 weeks of trastuzumab treatment. Methods: In a prospective cohort study, 45 patients with non-metastatic breast cancer (age 54, LVEF 62.8%, GLS -19.9%, 40% hypertension) scheduled for trastuzumab treatment were included. Echocardiography and measurement of troponin and NT-proBrain-Natriuretic-Peptide were conducted before initiation of trastuzumab, at days 3, 7, and 14 and after 3, 6, and 9 months. Results: A significant deterioration in LVEF from 62.8% (SD±3.6) to 58.4% (SD±4.1) (p < 0.0001), GLS from -19.9 (SD±2.1) to -18.1 (SD±2.5) (p = 0.004), s’ (p < 0.0001), e’ septal (p = 0.008), and s’ RV (p < 0.0001) occurred at 9 months and was preceded by significant changes in these parameters within the first 14 days. After 14 days, 12 patients (27%) had a ≥10% deterioration in GLS, which was associated with significantly lower LVEF at 55.2% (SD±4.1) at 9 months compared to patients with < 10% early deterioration in GLS (LVEF = 59.5% (SD±3.5) (p = 0.001)). No difference in plasma concentrations of biomarkers was observed between the two groups. Conclusion: In this study deteriorations in key echocardiographic parameters within normal limits were detected during the first 2 weeks of trastuzumab treatment, and an early ≥10% deterioration in GLS was associated with a lower LVEF at 9 months.
AB - Background: Global longitudinal strain (GLS) is recommended to detect subclinical changes preceding reduced left ventricular ejection fraction (LVEF) in trastuzumab related cardiotoxicity. Since the possibility to detect signs of acute myocardial deterioration at treatment initiation is not clarified, the objective of this study was to assess changes in GLS and biomarkers within the first 2 weeks of trastuzumab treatment. Methods: In a prospective cohort study, 45 patients with non-metastatic breast cancer (age 54, LVEF 62.8%, GLS -19.9%, 40% hypertension) scheduled for trastuzumab treatment were included. Echocardiography and measurement of troponin and NT-proBrain-Natriuretic-Peptide were conducted before initiation of trastuzumab, at days 3, 7, and 14 and after 3, 6, and 9 months. Results: A significant deterioration in LVEF from 62.8% (SD±3.6) to 58.4% (SD±4.1) (p < 0.0001), GLS from -19.9 (SD±2.1) to -18.1 (SD±2.5) (p = 0.004), s’ (p < 0.0001), e’ septal (p = 0.008), and s’ RV (p < 0.0001) occurred at 9 months and was preceded by significant changes in these parameters within the first 14 days. After 14 days, 12 patients (27%) had a ≥10% deterioration in GLS, which was associated with significantly lower LVEF at 55.2% (SD±4.1) at 9 months compared to patients with < 10% early deterioration in GLS (LVEF = 59.5% (SD±3.5) (p = 0.001)). No difference in plasma concentrations of biomarkers was observed between the two groups. Conclusion: In this study deteriorations in key echocardiographic parameters within normal limits were detected during the first 2 weeks of trastuzumab treatment, and an early ≥10% deterioration in GLS was associated with a lower LVEF at 9 months.
KW - Breast cancer
KW - Cardio toxicity
KW - Left ventricular function
KW - Longitudinal strain
KW - Trastuzumab
U2 - 10.1111/echo.15190
DO - 10.1111/echo.15190
M3 - Journal article
C2 - 34510537
AN - SCOPUS:85114667250
VL - 38
SP - 1702
EP - 1710
JO - Echocardiography: A Journal of Cardiovascular Ultrasound and Allied Techniques
JF - Echocardiography: A Journal of Cardiovascular Ultrasound and Allied Techniques
SN - 0742-2822
IS - 10
ER -
ID: 301448130